Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Real-time Quote. Real-time Tradegate - 01/24 10:20:45 am
62.89 EUR   -0.10%
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary..
01/18 UCB : Transparency notification
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
01/18/2017 01/19/2017 01/20/2017 01/23/2017 01/24/2017 Date
64.313(c) 63.73(c) 63.219(c) 62.955(c) 63 Last
0 100 0 26 20 Volume
+0.58% -0.91% -0.80% -0.42% +0.07% Change
More quotes
Financials (€)
Sales 2016 4 058 M
EBIT 2016 749 M
Net income 2016 472 M
Debt 2016 910 M
Yield 2016 1,92%
Sales 2017 4 319 M
EBIT 2017 902 M
Net income 2017 579 M
Debt 2017 565 M
Yield 2017 2,11%
P/E ratio 2016 24,16
P/E ratio 2017 19,62
EV / Sales2016 3,25x
EV / Sales2017 2,97x
Capitalization 12 275 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy &h..
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency Notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/06 Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
01/05 DERMIRA : Elects Emmanuel Caeymaex to Board of Directors
More news
Sector news : Pharmaceuticals - NEC
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 76,7 €
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA3.01%13 183
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
NOVARTIS AG-4.32%183 809
MERCK & CO., INC.4.99%170 419
More Results